Immunovant, Inc.
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991202686.htm EX-99.1 Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD),
Girao Tiago (Chief Financial Officer) sold 6,798 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.26M total) on 2026-07-23.
Stout Jay S (Chief Technology Officer) sold 2,857 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.11M total) on 2026-07-23.
Over the past 7 days, alphai's AI scored 1 news story mentioning IMVT (Immunovant, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IMVT coverage spans insider activity and earnings.
In the last 30 days, IMVT insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($433K). The most active reporter was Pande Atul with 1 filing. 33% of activity was filed under pre-arranged Rule 10b5-1 plans.
The filing updates cash runway and R&D burn while reiterating IMVT-1402 development timing, which can shift biotech risk appetite and near-term valuation expectations.
Routine insider open-market sale by the CFO, with no 10b5-1 plan cited, may slightly affect near-term sentiment but is not a fundamental catalyst.
This is a routine insider open-market sale with no 10b5-1 plan disclosed; it may slightly affect sentiment but is not a fundamental catalyst.
This is a routine insider sale under a Form 4, with no 10b5-1 plan cited, but it does not disclose new company fundamentals.
This is a routine insider open-market sale with no stated 10b5-1 plan; it may slightly affect sentiment but is not a fundamental catalyst.
alphai scores every news story that mentions IMVT with an AI model for sentiment and relevance, and aggregates insider trades from Immunovant, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991202686.htm EX-99.1 Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD),
4 min readGirao Tiago (Chief Financial Officer) sold 6,798 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.26M total) on 2026-07-23.
2 min readStout Jay S (Chief Technology Officer) sold 2,857 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.11M total) on 2026-07-23.
1 min readStout Jay S (Chief Technology Officer) sold 3,487 shares of Immunovant, Inc. (IMVT) at an average of $39.55 ($39.53–$39.99, $0.14M total) across 4 trades on 2026-07-08.
1 min readVenker Eric (Chief Executive Officer) sold 3,092 shares of Immunovant, Inc. (IMVT) at $38.48 ($0.12M total) on 2026-07-02.
1 min readVenker Eric (Chief Executive Officer) sold (to issuer) 86,629 shares of Immunovant, Inc. (IMVT) at $38.14 ($3.30M total) on 2026-07-01.
1 min readGloria Melanie (Chief Operating Officer) sold 17,714 shares of Immunovant, Inc. (IMVT) at an average of $38.31 ($38.18–$38.95, $0.68M total) across 2 trades on 2026-06-26.
3 min readStout Jay S (Chief Technology Officer) sold 40,000 shares of Immunovant, Inc. (IMVT) at an average of $38.31 ($38.18–$38.94, $1.53M total) across 2 trades on 2026-06-26.
2 min readVan Tuyl Christopher (Chief Legal Officer) sold 17,824 shares of Immunovant, Inc. (IMVT) at an average of $38.31 ($38.19–$38.96, $0.68M total) across 2 trades on 2026-06-26.
1 min readGirao Tiago (Chief Financial Officer) sold 10,000 shares of Immunovant, Inc. (IMVT) at $38.46 ($0.38M total) on 2026-06-26.
2 min read